| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
Published online before print June 28, 2007
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
,,,
,,,,@
From the Division of Infection and Immunity,* the Department of Clinical Science at South Bristol, University of Bristol, Bristol, United Kingdom; the Department of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; and SP Biopharma, Palo Alto, California
@ To whom correspondence should be addressed. E-mail: a.dick{at}bristol.ac.uk.
 |
Abstract |
|---|
Macrophage responses are regulated by multiple secreted factors as well as by cell surface receptors, including the inhibitory signals resulting from ligation of myeloid CD200 receptors (CD200R) by the widely distributed CD200. In the absence of CD200, animals display increased susceptibility to autoimmunity and earlier onset aggressive autoimmune disease. In these current experiments, an agonist monoclonal rat anti-mouse CD200R (DX109) antibody delivered a negative signal to bone marrow-derived macrophages, which suppressed interferon (IFN)
-mediated nitric oxide (NO) and interleukin-6 production. Experimental autoimmune uveoretinitis (EAU) was used as a model of organ-specific autoimmunity in the eye, a tissue with extensive neuronal and endothelial CD200 expression. In mice lacking CD200 (CD200-/-), increased numbers of retina-infiltrating macrophages displaying heightened NO responses were observed during EAU. In addition, we aimed to suppress disease by maintaining tonic suppression of macrophage activation via CD200R. Systemically administered DX109 monoclonal antibody suppressed EAU despite maintained T-cell proliferation and IFN production. Furthermore, locally administered DX109 monoclonal antibody resulted in an earlier resolution of disease. These experiments demonstrate that promoting CD200R-mediated signaling can successfully prevent full expression of IFN-mediated macrophage activation and protect against tissue damage during autoimmune responses.
This article has been cited by other articles:
 |
|
 |
|
  D. A. Copland, M. S. Wertheim, W. J. Armitage, L. B. Nicholson, B. J. E. Raveney, and A. D. Dick The Clinical Time-Course of Experimental Autoimmune Uveoretinitis Using Topical Endoscopic Fundal Imaging with Histologic and Cellular Infiltrate Correlation Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5458 - 5465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. E. Raveney, D. A. Copland, L. B. Nicholson, and A. D. Dick Fingolimod (FTY720) as an Acute Rescue Therapy for Intraocular Inflammatory Disease Arch Ophthalmol, October 1, 2008; 126(10): 1390 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. E. Raveney, C. Richards, M.-L. Aknin, D. A. Copland, B. R. Burton, E. Kerr, L. B. Nicholson, N. A. Williams, and A. D. Dick The B Subunit of Escherichia coli Heat-Labile Enterotoxin Inhibits Th1 but Not Th17 Cell Responses in Established Experimental Autoimmune Uveoretinitis Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4008 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gorczynski, I. Khatri, L. Lee, and I. Boudakov An Interaction between CD200 and Monoclonal Antibody Agonists to CD200R2 in Development of Dendritic Cells That Preferentially Induce Populations of CD4+CD25+ T Regulatory Cells J. Immunol., May 1, 2008; 180(9): 5946 - 5955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Feuer Tickling the CD200 Receptor: A Remedy for Those Irritating Macrophages Am. J. Pathol., August 1, 2007; 171(2): 396 - 398. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
